A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
Public ClinicalTrials.gov record NCT03436615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Ascending Dose Study of SB206 in Subjects With Molluscum Contagiosum
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
Study identification
- NCT ID
- NCT03436615
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 256 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 2 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 24, 2018 (Actual)
- Primary completion
- Nov 3, 2018 (Actual)
- Completion
- Nov 3, 2018 (Actual)
- Last update posted
- May 6, 2023
2018
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Premier Site# 266 | Scottsdale | Arizona | 85255 | — |
| Premier Site# 260 | Santa Ana | California | 92701 | — |
| Premier Site# 257 | Thornton | Colorado | 80233 | — |
| Premier Site# 264 | Doral | Florida | 33172 | — |
| Premier Site# 116 | Newnan | Georgia | 30263 | — |
| Premier Site# 251 | Indianapolis | Indiana | 46256 | — |
| Premier Site# 253 | Lenexa | Kansas | 66215 | — |
| Premier Site# 117 | Louisville | Kentucky | 40241 | — |
| Premier Site# 182 | Las Vegas | Nevada | 89129 | — |
| Premier Site# 252 | Norman | Oklahoma | 73071 | — |
| Premier Site# 237 | Gresham | Oregon | 97030 | — |
| Premier Site# 259 | Charleston | South Carolina | 29414 | — |
| Premier Site# 255 | Mt. Pleasant | South Carolina | 29464 | — |
| Premier Site# 131 | Houston | Texas | 77004 | — |
| Premier Site# 167 | Houston | Texas | 77030 | — |
| Premier Site# 224 | San Antonio | Texas | 78218 | — |
| Premier Site# 256 | Salt Lake City | Utah | 84124 | — |
| Premier Site# 267 | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03436615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2023 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03436615 live on ClinicalTrials.gov.